Esophageal Cancer | Topics

 
Biologics License Applications Accepted for Nivolumab/Ipilimumab and Nivolumab/Chemo for Unresectable Advanced ESCC
October 04, 2021

Treatment with nivolumab/ipilimumab and nivolumab/chemotherapy has demonstrated efficacy in unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma, with results from the CheckMate-648 trial leading to the acceptance of the regimens’ applications by the FDA.

Pembrolizumab Plus Chemotherapy Combination Improves Survival in Esophageal Squamous Cell Carcinoma
September 21, 2021

Pembrolizumab plus chemotherapy compared with the placebo plus chemotherapy demonstrated an improvement in overall survival and progression-free survival for patients with esophageal squamous cell carcinoma.

Patients With Frontline Gastric/GEJ Cancers Benefit When Nivolumab Is Added to Chemotherapy
September 19, 2021

Data presented at 2021 ESMO show that nivolumab plus chemotherapy improves survival outcomes in certain patients with frontline gastrointestinal cancers, but not nivolumab plus ipilimumab.

Patients With Esophageal Squamous Cell Carcinoma Treated With Frontline Toripalimab Plus Chemo Derive Survival Benefit
September 18, 2021

Results from the phase 3 JUPITER06 trial demonstrated positive outcomes with toripalimab plus platinum-based chemotherapy in patients with treatment-naïve advanced or metastatic esophageal squamous cell carcinoma.

Patients with Advanced Esophageal Cancers Benefit From Addition of Sintilimab
September 17, 2021

Results of 2 studies presented at 2021 ESMO demonstrate superior efficacy of sintilimab plus chemotherapy versus chemotherapy alone in certain gastrointestinal cancers.

Tiragolumab/Atezolizumab Demonstrate Promising Preliminary Activity in Metastatic Esophageal Cancer
July 12, 2021

Preliminary data from the phase 1b GO30103 study indicated that the combination of tiragolumab plus atezolizumab may have promise in patients with heavily pretreated metastatic esophageal cancer.

Nivolumab Combinations Superior to Chemotherapy Alone for Metastatic Esophageal Cancer
June 03, 2021

Survival outcomes improved when nivolumab was added to either ipilimumab or chemotherapy versus chemotherapy alone in advanced/metastatic esophageal squamous cell carcinoma

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy
February 28, 2021

Data from the Journal of the American College of Surgeons suggest patients 70 years or older with esophageal or esophagogastric junction cancers should be evaluated for optimal curative therapy.

Tislelizumab Improves OS Compared With Chemo in Advanced Unresectable or Metastatic ESCC
January 28, 2021

The phase 3 RATIONALE 302 trial demonstrated that compared to chemotherapy, tislelizumab showed a statistically significant and clinically meaningful improvement in overall survival in the intention-to-treat population of patients with advanced or metastatic esophageal squamous cell carcinoma.

Farshid Dayyani, MD, PhD, Discusses Multidisciplinary Approach to Research on Treatment for Gastroesophageal Adenocarcinoma
January 17, 2021

A leading expert in the field of esophageal cancers discussed his upcoming research on cabozantinib combined with pembrolizumab to treat gastroesophageal adenocarcinoma at the 2021 ASCO Gastrointestinal Cancers Symposium.